0001193125-20-005890.txt : 20200113 0001193125-20-005890.hdr.sgml : 20200113 20200113071209 ACCESSION NUMBER: 0001193125-20-005890 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200113 DATE AS OF CHANGE: 20200113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 20522747 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 8-K 1 d760527d8k.htm 8-K 8-K
false 0001503802 0001503802 2020-01-13 2020-01-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 13, 2020

 

Karyopharm Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

  

001-36167

  

26-3931704

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

85 Wells Avenue, 2nd Floor

Newton, Massachusetts

  

02459

(Address of Principal Executive Offices)

  

(Zip Code)

Registrant’s telephone number, including area code: (617) 658-0600

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value

  

KPTI

  

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ 

 

 

Item 2.02. Results of Operations and Financial Condition.

On January 13, 2020, Karyopharm Therapeutics Inc. (the “Company”) announced its preliminary unaudited fourth quarter and full year 2019 net product revenues for XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and provided additional updates on the product’s commercial launch. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

 

99.1

   

Press release issued by Karyopharm Therapeutics Inc. on January 13, 2020.

         
 

104

   

Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

KARYOPHARM THERAPEUTICS INC.

             

Date: January 13, 2020

 

 

By:

 

/s/ Christopher B. Primiano

 

 

 

Christopher B. Primiano

 

 

 

Executive Vice President, Chief Business Officer,

General Counsel and Secretary

EX-99.1 2 d760527dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

             LOGO    Targeting Disease at the Nuclear Pore

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update

— XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Full Year 2019 —

— Approximately 1,400 XPOVIO Prescriptions Fulfilled in the U.S. from Launch Through Year End 2019 —

NEWTON, Mass. – January 13, 2020 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced preliminary unaudited fourth quarter and full year 2019 net product sales for XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and provided additional updates on the product’s commercial launch.

Strong XPOVIO Commercial Rollout Continues in the U.S.

Oral XPOVIO tablets became commercially available to patients in the U.S. on July 9, 2019. Based on preliminary unaudited financial information, Karyopharm expects net product sales of XPOVIO to be between $17 and $18 million during the fourth quarter and between $30 and $31 million for the full year 2019. As of December 31, 2019, approximately 1,400 XPOVIO prescriptions have been fulfilled, driven by strong demand from both academic and community-based oncologists. In less than 6 months on the market, XPOVIO has been prescribed by more than 550 unique physicians and healthcare accounts. These updates will be discussed during a webcast presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020 at 10:00 a.m. PT (1:00 p.m. ET). A live webcast of the presentation and Q&A session can be accessed through the investor section of the Company’s website at www.karyopharm.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.

“By all accounts, 2019 was a transformational year for Karyopharm with the accelerated approval and commercial launch of XPOVIO, the first and only oral nuclear export inhibitor approved in the U.S., indicated for patients with heavily pretreated multiple myeloma,” said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. “We are extremely pleased with the commercial launch of XPOVIO thus far, including the breadth of prescribing physicians and early feedback from patients who have initiated therapy. We are proud to be making such an important impact for patients who are battling relapsed or refractory multiple myeloma.”

The Company intends to provide 2020 financial guidance on non-GAAP R&D and SG&A expenses and year-end cash balance in connection with the final financial results for the fourth quarter and audited financial results for full year 2019 expected to be provided in February 2020.

The financial information presented in this press release may be adjusted as a result of the completion of customary quarterly review and audit procedures, and the Company’s actual financial results may differ materially from the preliminary estimated financial information set forth above.

             LOGO    Targeting Disease at the Nuclear Pore

 

About XPOVIO® (selinexor)

XPOVIO is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1). XPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. The forced nuclear retention of these proteins can counteract a multitude of the oncogenic pathways that, unchecked, allow cancer cells with severe DNA damage to continue to grow and divide in an unrestrained fashion. In addition to receiving accelerated U.S. Food and Drug Administration (FDA) approval of XPOVIO in July 2019 in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody, Karyopharm has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) with a request for conditional approval of selinexor. A New Drug Application was recently submitted to the FDA seeking accelerated approval for selinexor as a new treatment for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Selinexor has received Fast Track and Orphan designation from the FDA for the patient population evaluated in the SADAL study. Selinexor is also being evaluated in several other mid-and later-phase clinical trials across multiple cancer indications, including in multiple myeloma in a pivotal, randomized Phase 3 study in combination with Velcade® (bortezomib) and low-dose dexamethasone (BOSTON), as a potential backbone therapy in combination with approved therapies (STOMP), in liposarcoma (SEAL) and in endometrial cancer (SIENDO), among others. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with approved therapies in a variety of tumor types to further inform Karyopharm’s clinical development priorities for selinexor. Additional clinical trial information for selinexor is available at www.clinicaltrials.gov.

IMPORTANT SAFETY INFORMATION

Thrombocytopenia

XPOVIO can cause thrombocytopenia, leading to potentially fatal hemorrhage. Thrombocytopenia was reported as an adverse reaction in 74% of patients, and severe (Grade 3-4) thrombocytopenia occurred in 61% of patients treated with XPOVIO. The median time to onset of the first event was 22 days. Bleeding occurred in 23% of patients with thrombocytopenia, clinically significant bleeding occurred in 5% of patients with thrombocytopenia and fatal hemorrhage occurred in <1% of patients.

Monitor platelet counts at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Institute platelet transfusion and/or other treatments as clinically indicated. Monitor patients for signs and symptoms of bleeding and evaluate promptly. Interrupt and/or reduce dose, or permanently discontinue based on severity of adverse reaction.

             LOGO    Targeting Disease at the Nuclear Pore

 

Neutropenia

XPOVIO can cause neutropenia, potentially increasing the risk of infection. Neutropenia was reported as an adverse reaction in 34% of patients, and severe (Grade 3-4) neutropenia occurred in 21% of patients treated with XPOVIO. The median time to onset of the first event was 25 days. Febrile neutropenia was reported in 3% of patients.

Obtain neutrophil counts at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Monitor patients for signs and symptoms of concomitant infection and evaluate promptly. Consider supportive measures including antimicrobials for signs of infection and use of growth factors (e.g., G-CSF). Interrupt and/or reduce dose, or permanently discontinue based on severity of adverse reaction.

Gastrointestinal Toxicity

Gastrointestinal toxicities occurred in patients treated with XPOVIO.

Nausea/Vomiting

Nausea was reported as an adverse reaction in 72% of patients, and Grade 3 nausea occurred in 9% of patients treated with XPOVIO. The median time to onset of the first nausea event was 3 days.

Vomiting was reported in 41% of patients, and Grade 3 vomiting occurred in 4% of patients treated with XPOVIO. The median time to onset of the first vomiting event was 5 days.

Provide prophylactic 5-HT3 antagonists and/or other anti-nausea agents, prior to and during treatment with XPOVIO. Manage nausea/vomiting by dose interruption, reduction, and/or discontinuation. Administer intravenous fluids and replace electrolytes to prevent dehydration in patients at risk. Use additional anti-nausea medications as clinically indicated.

Diarrhea

Diarrhea was reported as an adverse reaction in 44% of patients, and Grade 3 diarrhea occurred in 6% of patients treated with XPOVIO. The median time to onset of diarrhea was 15 days.

Manage diarrhea by dose modifications and/or standard anti-diarrheal agents; administer intravenous fluids to prevent dehydration in patients at risk.

Anorexia/Weight Loss

Anorexia was reported as an adverse reaction in 53% of patients, and Grade 3 anorexia occurred in 5% of patients treated with XPOVIO. The median time to onset of anorexia was 8 days.

Weight loss was reported as an adverse reaction in 47% of patients, and Grade 3 weight loss occurred in 1% of patients treated with XPOVIO. The median time to onset of weight loss was 15 days.

Monitor patient weight at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Manage anorexia and weight loss with dose modifications, appetite stimulants, and nutritional support.

             LOGO    Targeting Disease at the Nuclear Pore

 

Hyponatremia

XPOVIO can cause hyponatremia; 39% of patients treated with XPOVIO experienced hyponatremia, 22% of patients experienced Grade 3 or 4 hyponatremia. The median time to onset of the first event was 8 days.

Monitor sodium level at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Correct sodium levels for concurrent hyperglycemia (serum glucose >150 mg/dL) and high serum paraprotein levels. Treat hyponatremia per clinical guidelines (intravenous saline and/or salt tablets), including dietary review. Interrupt and/or reduce dose, or permanently discontinue based on severity of adverse reaction.

Infections

In patients receiving XPOVIO, 52% of patients experienced any grade of infection. Upper respiratory tract infection of any grade occurred in 21%, pneumonia in 13%, and sepsis in 6% of patients. Grade ³3 infections were reported in 25% of patients, and deaths resulting from an infection occurred in 4% of patients. The most commonly reported Grade ³3 infections were pneumonia in 9% of patients, followed by sepsis in 6%. The median time to onset was 54 days for pneumonia and 42 days for sepsis. Most infections were not associated with neutropenia and were caused by non-opportunistic organisms.

Neurological Toxicity

Neurological toxicities occurred in patients treated with XPOVIO.

Neurological adverse reactions including dizziness, syncope, depressed level of consciousness, and mental status changes (including delirium and confusional state) occurred in 30% of patients, and severe events (Grade 3-4) occurred in 9% of patients treated with XPOVIO. Median time to the first event was 15 days.

Optimize hydration status, hemoglobin level, and concomitant medications to avoid exacerbating dizziness or mental status changes.

Embryo-Fetal Toxicity

Based on data from animal studies and its mechanism of action, XPOVIO can cause fetal harm when administered to a pregnant woman. Selinexor administration to pregnant animals during organogenesis resulted in structural abnormalities and alterations to growth at exposures below those occurring clinically at the recommended dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with a female partner of reproductive potential to use effective contraception during treatment with XPOVIO and for 1 week after the last dose.

ADVERSE REACTIONS

The most common adverse reactions (incidence ³20%) are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection.

             LOGO    Targeting Disease at the Nuclear Pore

 

The treatment discontinuation rate due to adverse reactions was 27%; 53% of patients had a reduction in the XPOVIO dose, and 65.3% had the dose of XPOVIO interrupted. The most frequent adverse reactions requiring permanent discontinuation in 4% or greater of patients who received XPOVIO included fatigue, nausea, and thrombocytopenia. The rate of fatal adverse reactions was 8.9%.

Please see XPOVIO Full Prescribing Information available at www.XPOVIO.com.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. An MAA for selinexor is also currently under review by the EMA for the same indication. The Company recently submitted a New Drug Application to the FDA seeking approval for XPOVIO in patients with DLBCL. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm’s preliminary financial information for fourth quarter and full year 2019; Karyopharm’s plans to provide guidance on its 2020 non-GAAP R&D and SG&A expenses and year-end cash balance; expectations relating to XPOVIO for the treatment of patients with heavily pretreated multiple myeloma or relapsed or refractory diffuse large B-cell lymphoma; commercialization of XPOVIO or any of its drug candidates and the commercial performance of XPOVIO; submissions to, and the review and potential approval of selinexor by, regulatory authorities, including the anticipated availability of data to support such submissions, timing of such submissions and actions by regulatory authorities and the potential availability of accelerated approval pathways; and the therapeutic potential of and potential clinical development plans for Karyopharm’s drug candidates, especially selinexor. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm’s control, that may cause actual events or results to differ materially from Karyopharm’s current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO; that regulators will agree that selinexor qualifies for conditional approval in the E.U. as a result of data from the STORM study or confirmatory approval in the U.S. or EU based on the BOSTON study in patients with relapsed or refractory multiple myeloma, or accelerated approval in the U.S. for patients with relapsed or refractory DLBCL as a result of data from the SADAL study, or that any of Karyopharm’s drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm’s drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm’s drug candidate portfolio will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: items that may be identified during Karyopharm’s financial statement closing process that cause adjustments to the estimates included in this press release; adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm’s drug candidates that receive regulatory approval; the ability to

             LOGO    Targeting Disease at the Nuclear Pore

 

retain regulatory approval of XPOVIO or any of Karyopharm’s drug candidates that receive regulatory approval; Karyopharm’s results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical studies; the ability of Karyopharm or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; Karyopharm’s ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm’s competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm’s ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption “Risk Factors” in Karyopharm’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, which was filed with the Securities and Exchange Commission (SEC) on November 4, 2019, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Velcade® is a registered trademark of Takeda Pharmaceutical Company Limited

Contacts:

Investors:

Karyopharm Therapeutics Inc.

Ian Karp, Vice President, Investor and Public Relations

857-297-2241 | ikarp@karyopharm.com

Media:

FTI Consulting

Simona Kormanikova or Robert Stanislaro

212-850-5600 |Simona.Kormanikova@fticonsulting.com or robert.stanislaro@fticonsulting.com

EX-101.SCH 3 kpti-20200113.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 kpti-20200113_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 kpti-20200113_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g760527g0110075450793.jpg GRAPHIC begin 644 g760527g0110075450793.jpg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end XML 7 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d760527d8k.htm d760527dex991.htm kpti-20200113.xsd kpti-20200113_lab.xml kpti-20200113_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 d760527d8k_htm.xml IDEA: XBRL DOCUMENT 0001503802 2020-01-13 2020-01-13 false 0001503802 8-K 2020-01-13 Karyopharm Therapeutics Inc. DE 001-36167 26-3931704 85 Wells Avenue 2nd Floor Newton MA 02459 (617) 658-0600 false false false false Common Stock, $0.0001 par value KPTI NASDAQ false XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} ZIP 11 0001193125-20-005890-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-005890-xbrl.zip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end JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d760527d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d760527d8k.htm" ] }, "labelLink": { "local": [ "kpti-20200113_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "kpti-20200113_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "kpti-20200113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "kpti", "nsuri": "http://www.karyopharm.com/20200113", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d760527d8k.htm", "contextRef": "duration_2020-01-13_to_2020-01-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d760527d8k.htm", "contextRef": "duration_2020-01-13_to_2020-01-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 13 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information
Jan. 13, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001503802
Document Type 8-K
Document Period End Date Jan. 13, 2020
Entity Registrant Name Karyopharm Therapeutics Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-36167
Entity Tax Identification Number 26-3931704
Entity Address, Address Line One 85 Wells Avenue
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Newton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02459
City Area Code (617)
Local Phone Number 658-0600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value
Trading Symbol KPTI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

EXCEL 15 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end